AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2003 NOV 5 - (NewsRx.com & NewsRx.net) -- Results from a randomized placebo-controlled trial indicate that a virosome hepatitis A vaccine is efficacious in young children in Nicaragua.
"Immunization of young children could control hepatitis A virus (HAV) infection, but the efficacy of hepatitis A vaccines in early childhood is unknown. In a randomized, double-blind trial of a single dose of a virosome-formulated, aluminum-free inactivated HAV vaccine in Nicaragua, 274 children (age range, 1.5-6 years) received vaccine or placebo injections; 239 children seronegative for hepatitis A were included in the primary efficacy analysis," an international team of scientists reports.
"HAV infection documented by immunoglobulin M antibodies was the primary end point," stated Orlando Mayorga Perez at the University of Leon in Nicaragua and collaborators in Nicaragua, Switzerland, Germany, and UK. "Among children seronegative for hepatitis A, infection was diagnosed in 4 children in the vaccine group and 22 children in the placebo group (protective efficacy, 84.6%; 95% confidence interval, 54.7%-96.1%). All infections in children in the vaccine group occurred within six weeks. After six weeks, protective efficacy was 100% (79.8%-100%). In children in ...
Source: HighBeam Research, Virosome hepatitis A vaccine efficacious in young children in...